The tyrosine kinase ephrin type-A receptor 2 (EPHA2) was remarkably elevated expressed in various tumors and plays a crucial role in cancer tumorigenesis and progression, while pan-cancer analyses are currently lacking. This study was designed to analyze the expression status and prognostic significance of EPHA2 in pan-cancer. By mining The Cancer Genome Atlas data, we performed a comprehensive and systematic characterization of EPHA2 across >10,000 samples of 33 types of cancer. EPHA2 expressions were substantially different in most of the normal control and tumor tissues, and it was considerably associated with the prognosis of tumor patients. EPHA2 gene modifications in malignant tumors were mainly missense mutations. There was a significant correlation between EPHA2 expression and cancer-associated fibroblasts in most The Cancer Genome Atlas cancers. Furthermore, functional enrichment analysis showed that the biological role of EPHA2 in tumors was mainly involved in some noticeably pro-oncogenic pathways, such as the Ras signaling pathway, PI3K-Akt signaling pathway, ErbB signaling pathway, MAPK signaling pathway, etc. This study provided the first pan-cancer analyses of EPHA2 in various tumors, and EPHA2 was potentially involved in many cancer types and can be developed as candidates for cancer diagnosis, prognosis, and therapeutic biomarkers. In addition, EPHA2 seemed to be a key modulator of the tumor immune microenvironment and might be a potential biomarker in predicting the immunotherapeutic efficacy for cancer patients.
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.